The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites

• Published in: Molecular psychiatry Vol. 26; no. 7; pp. 3419 - 3429
• Main Authors: Bartoli, Francesco, Misiak, Błażej, Callovini, Tommaso, Cavaleri, Daniele, Cioni, Riccardo M., Crocamo, Cristina, Savitz, Jonathan B., Carrà, Giuseppe
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.07.2021; Nature Publishing Group
• Subjects: 631/337; 692/53; Acids; Adult; Behavioral Sciences; Biological Psychology; Bipolar Disorder; Blood levels; Cellular signal transduction; Development and progression; Health aspects; Humans; Kynurenic Acid; Kynurenine; Medicine; Medicine & Public Health; Meta-analysis; Metabolites; Neurosciences; Observational Studies as Topic; Peripheral blood; Pharmacotherapy; Psychiatry; Psychological aspects; Quinolinic Acid; Sensitivity analysis; Systematic review; Tryptophan; Tryptophan metabolism; Xanthurenic acid; Italy
• ISSN: 1359-4184; 1476-5578; 1476-5578
• DOI: 10.1038/s41380-020-00913-1

Growing evidence suggests that a dysregulation of the kynurenine pathway (KP) occurs in bipolar disorder (BD). This systematic review and meta-analysis aimed at assessing the possible differences in peripheral blood levels of KP metabolites between individuals with BD and healthy controls. We searched Medline, Embase, and PsycInfo electronic databases for articles indexed up to February 2020. We included any observational study comparing the peripheral blood levels of at least one KP metabolite between adults with BD and healthy controls. Random-effects meta-analyses were carried out generating pooled standardized mean differences (SMDs). Heterogeneity between studies was estimated using the I 2 index. Meta-regression and sensitivity analyses were conducted. Sixteen studies met inclusion criteria and were included in our study. Meta-analyses showed that individuals with BD have lower peripheral blood levels of tryptophan (SMD = −0.29), kynurenine (SMD = −0.28), kynurenic acid (SMD = −0.30), and xanthurenic acid (SMD = −0.55), along with lower kynurenic acid to kynurenine (SMD = −0.60) and kynurenic acid to quinolinic acid (SMD = −0.37) ratios, than healthy controls. Individuals with a manic episode showed the greatest reductions in tryptophan levels (SMD = −0.51), whereas kynurenic acid levels were more reduced among subjects in a depressive phase (SMD = −0.70). Meta-regression and sensitivity analyses confirmed our results. The findings of the present meta-analysis support the hypothesis of an abnormality of the KP in BD. Considering the partial inconsistency of the findings and the small-to-medium magnitude of the estimated effect sizes, additional research assessing possible mediators or confounders is needed.